Latest Regulatory Filings News

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Vonex Limited reported a net cash inflow of $779,000 from operating activities in Q4 2024, maintaining a solid cash position despite accelerated debt repayments following a change of control.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Nexus Minerals reports significant exploration success at its Wallbrook Gold Project with two new gold discoveries and robust assay results from a recent aircore drilling campaign. The company plans further drilling to expand these promising targets.

Icetana Limited reports a sharp decline in cash flow for the December quarter, offset by plans for an underwritten rights issue to bolster funding and expectations of improved customer receipts in coming quarters.

Scalare Partners reports robust progress in Q2 FY25, highlighted by a $4.3 million capital raise, expansion of its Tech Ready Women program, and a growing investment portfolio. The company is poised for its next growth phase with a strong cash position and a healthy pipeline of early-stage tech investments.

New Frontier Minerals has entered a strategic alliance with Austral Resources to process copper ore from its Big One Deposit, aiming to accelerate production and exploration in the Mt Isa copper belt.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Vonex Limited has vested performance rights for its CEO and directors following MaxoTel’s acquisition of majority control, with shares set to be sold on-market. The company reports a mixed 1H FY25 financial performance and is exploring options to repay a $23 million debt facility, including a potential capital raise.

Magnetic Resources NL reported a $4.39 million net cash outflow from operations in Q4 2024 but strengthened its balance sheet with a $9.41 million financing inflow, ending the quarter with $11.6 million in cash.